Who is involved
As the world continues to grapple with the COVID-19 pandemic, the emergence of new variants has become a familiar narrative. Before the arrival of the Cicada variant, designated BA.3.2, there was a sense of cautious optimism. Vaccination campaigns were underway, and many hoped that the worst of the pandemic was behind them. The Omicron variant had already shown itself to be more transmissible but less severe than earlier strains, leading to a belief that the virus was evolving towards a more manageable presence in society.
However, a decisive moment arrived in March 2026 when the Cicada variant was reported in the UK, following its initial detection in South Africa in November 2024. This new strain has since been confirmed in 24 countries, raising alarms among health officials. The Cicada variant carries 70 to 75 genetic changes in its spike protein, which is significant enough to raise concerns about the effectiveness of existing vaccines. As of early 2026, it accounted for approximately 30% of COVID-19 sequences reported in Denmark, Germany, and the Netherlands, indicating a rapid spread.
The direct effects of this development have been felt across various sectors. Healthcare providers are bracing for potential increases in hospitalizations, which were already estimated to be between 390,000 and 550,000 during the 2024-25 respiratory virus season. The Cicada variant has been associated with symptoms such as a painful sore throat, fever, cough, fatigue, and nasal congestion, which could lead to a surge in cases. Public health officials are now faced with the challenge of managing this new threat while continuing to promote vaccination efforts.
Experts have weighed in on the implications of the Cicada variant. Kyle B. Enfield, a prominent epidemiologist, stated, “Because it’s significantly different, the current COVID-19 vaccine may not be as effective.” This sentiment is echoed by Ian Budd, who noted, “What’s different about it is the number of mutations it carries, particularly on the part of the virus that attaches to your cells.” The potential for the Cicada variant to evade antibodies has raised concerns about its impact on public health strategies.
Despite these worries, there is some reassurance. Enfield also mentioned, “There’s no sign so far that BA.3.2, nicknamed Cicada, is any more dangerous or causes more severe disease than the variants that were circulating in the winter of 2025-26.” This suggests that while the variant may be more transmissible, it does not necessarily lead to worse health outcomes for those infected.
The Cicada variant’s emergence has drawn comparisons to its namesake, the cicada insect, which lies dormant for years before emerging. This metaphor reflects the variant’s ability to remain undetected before spreading widely. The CDC has warned that the Cicada strain “could be associated with seasonal increases in COVID-19 activity,” indicating that it may become a recurring challenge in managing the pandemic.
As the UK and other countries navigate this new phase of the pandemic, uncertainties remain. The exact impact of the Cicada variant on public health is still unclear due to limited genomic detection and surveillance capacities in many countries. Additionally, the long-term effectiveness of current vaccines against this variant is uncertain. Details remain unconfirmed.
In this evolving landscape, the public is urged to remain vigilant and informed. The emergence of the Cicada variant serves as a reminder that the fight against COVID-19 is far from over, and continued adaptation and response will be crucial in safeguarding public health.
You may also like
